JP2024075737A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024075737A5 JP2024075737A5 JP2024048842A JP2024048842A JP2024075737A5 JP 2024075737 A5 JP2024075737 A5 JP 2024075737A5 JP 2024048842 A JP2024048842 A JP 2024048842A JP 2024048842 A JP2024048842 A JP 2024048842A JP 2024075737 A5 JP2024075737 A5 JP 2024075737A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- antibody variant
- combination
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 239000013604 expression vector Substances 0.000 claims 13
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 12
- 239000003981 vehicle Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 11
- 230000035772 mutation Effects 0.000 claims 9
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 102000052645 human CD38 Human genes 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008177 pharmaceutical agent Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 239000001825 Polyoxyethene (8) stearate Substances 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101710095468 Cyclase Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229960002204 daratumumab Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000005883 trogocytosis Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697730P | 2018-07-13 | 2018-07-13 | |
| US62/697,730 | 2018-07-13 | ||
| US201962848874P | 2019-05-16 | 2019-05-16 | |
| US62/848,874 | 2019-05-16 | ||
| JP2021500814A JP7526717B2 (ja) | 2018-07-13 | 2019-07-15 | Ｃｄ３８抗体のバリアントおよびその使用 |
| PCT/EP2019/069028 WO2020012036A1 (en) | 2018-07-13 | 2019-07-15 | Variants of cd38 antibody and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500814A Division JP7526717B2 (ja) | 2018-07-13 | 2019-07-15 | Ｃｄ３８抗体のバリアントおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024075737A JP2024075737A (ja) | 2024-06-04 |
| JP2024075737A5 true JP2024075737A5 (https=) | 2024-10-17 |
Family
ID=67396922
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500814A Active JP7526717B2 (ja) | 2018-07-13 | 2019-07-15 | Ｃｄ３８抗体のバリアントおよびその使用 |
| JP2024048842A Pending JP2024075737A (ja) | 2018-07-13 | 2024-03-26 | Ｃｄ３８抗体のバリアントおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500814A Active JP7526717B2 (ja) | 2018-07-13 | 2019-07-15 | Ｃｄ３８抗体のバリアントおよびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20200017600A1 (https=) |
| EP (1) | EP3820900A1 (https=) |
| JP (2) | JP7526717B2 (https=) |
| KR (1) | KR20210031932A (https=) |
| CN (2) | CN112513082B (https=) |
| AU (1) | AU2019300223A1 (https=) |
| BR (1) | BR112020026432A2 (https=) |
| CA (1) | CA3106146A1 (https=) |
| CL (1) | CL2021000066A1 (https=) |
| CO (1) | CO2021001544A2 (https=) |
| CR (1) | CR20210081A (https=) |
| DO (2) | DOP2021000006A (https=) |
| EC (1) | ECSP21010092A (https=) |
| IL (1) | IL279937A (https=) |
| MA (1) | MA53122A (https=) |
| MX (1) | MX2020013631A (https=) |
| MY (1) | MY205398A (https=) |
| PE (1) | PE20211858A1 (https=) |
| PH (1) | PH12021550054A1 (https=) |
| SG (1) | SG11202012993SA (https=) |
| TW (1) | TW202019518A (https=) |
| WO (1) | WO2020012036A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| US20200017600A1 (en) * | 2018-07-13 | 2020-01-16 | Genmab A/S | Variants of cd38 antibody and uses thereof |
| US20230272105A1 (en) * | 2020-01-16 | 2023-08-31 | Genmab A/S | Formulations of cd38 antibodies and uses thereof |
| JP2023529846A (ja) * | 2020-06-02 | 2023-07-12 | バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド | 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物 |
| US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| WO2023044346A2 (en) | 2021-09-14 | 2023-03-23 | Ausper Biopharma Co., Ltd. | Vaccines for coronavirus prevention and treatment |
| US20240400711A1 (en) * | 2021-09-23 | 2024-12-05 | Sound Biopharmaceuticals Co. Ltd. | Cd38 monoclonal antibody and application thereof |
| AU2022380155A1 (en) | 2021-11-03 | 2024-06-20 | Janssen Biotech, Inc. | Corticosteriod reduction in treatment with anti-cd38 antibodies |
| CN114409788B (zh) * | 2022-03-04 | 2022-10-04 | 四川大学华西医院 | 抗cd38的抗体及其应用 |
| TW202432177A (zh) | 2022-10-31 | 2024-08-16 | 丹麥商珍美寶股份有限公司 | Ｃｄ３８抗體及其用途 |
| WO2024131849A1 (zh) * | 2022-12-21 | 2024-06-27 | 非同（成都）生物科技有限公司 | Cd38单克隆抗体及其应用 |
| AU2024239150A1 (en) * | 2023-03-21 | 2025-10-02 | Biograph 55, Inc. | Cd19/cd38 multispecific antibodies |
| CN120965865B (zh) * | 2025-10-15 | 2026-01-16 | 内蒙古盛健生物科技有限责任公司 | 一种用于特异性治疗奶山羊羔羊口疮的抗体及其应用 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US835A (en) | 1838-07-12 | X i i i x | ||
| US6077A (en) | 1849-01-30 | Improved hinged claw-wrench | ||
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DK0486622T3 (da) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| WO2000046147A2 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| JP5225069B2 (ja) | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| WO2008037257A2 (en) | 2006-09-26 | 2008-04-03 | Genmab A/S | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| DK2786762T3 (da) | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CN102770456B (zh) | 2009-12-04 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| SMT202000031T1 (it) * | 2010-06-09 | 2020-03-13 | Genmab As | Anticorpi contro cd38 umano |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| JP6454547B2 (ja) * | 2011-07-06 | 2019-01-16 | ゲンマブ エー／エス | 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節 |
| RS60499B1 (sr) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| US9683044B2 (en) | 2012-08-20 | 2017-06-20 | Gliknik Inc. | Molecules with antigen binding and polyvalent FC gamma receptor binding activity |
| KR20200024345A (ko) | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| BR112015022855A2 (pt) | 2013-03-14 | 2017-11-07 | Shire Human Genetic Therapies | composições e método para produção de um anticorpo in vitro |
| EP3388834B1 (en) | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| US9862752B2 (en) * | 2013-07-31 | 2018-01-09 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| CA2945882A1 (en) | 2014-04-16 | 2015-10-22 | Ucb Biopharma Sprl | Multimeric fc proteins |
| EP4667492A3 (en) * | 2015-05-26 | 2026-04-15 | Ramot at Tel-Aviv University Ltd. | Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes |
| EA037548B1 (ru) | 2015-06-24 | 2021-04-12 | Янссен Байотек, Инк. | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 |
| CN109476737A (zh) * | 2015-12-01 | 2019-03-15 | 根马布有限公司 | 抗dr5抗体及其使用方法 |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| WO2017117528A1 (en) | 2015-12-30 | 2017-07-06 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| CN109563511A (zh) | 2016-06-30 | 2019-04-02 | 阿布特斯生物制药公司 | 用于递送信使rna的组合物和方法 |
| WO2018031258A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| US10526284B2 (en) | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| JP6931058B2 (ja) | 2016-12-21 | 2021-09-01 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗体のインビトロ糖鎖工学における酵素の再使用 |
| KR102317884B1 (ko) | 2016-12-21 | 2021-10-26 | 에프. 호프만-라 로슈 아게 | 항체의 시험관 내 당조작 |
| CN117887794A (zh) | 2016-12-21 | 2024-04-16 | 豪夫迈·罗氏有限公司 | 用于体外糖工程化抗体的方法 |
| US20200017600A1 (en) * | 2018-07-13 | 2020-01-16 | Genmab A/S | Variants of cd38 antibody and uses thereof |
-
2019
- 2019-07-15 US US16/512,206 patent/US20200017600A1/en not_active Abandoned
- 2019-07-15 WO PCT/EP2019/069028 patent/WO2020012036A1/en not_active Ceased
- 2019-07-15 EP EP19742548.1A patent/EP3820900A1/en active Pending
- 2019-07-15 MX MX2020013631A patent/MX2020013631A/es unknown
- 2019-07-15 JP JP2021500814A patent/JP7526717B2/ja active Active
- 2019-07-15 CN CN201980047066.7A patent/CN112513082B/zh active Active
- 2019-07-15 CR CR20210081A patent/CR20210081A/es unknown
- 2019-07-15 PE PE2021000038A patent/PE20211858A1/es unknown
- 2019-07-15 CN CN202511041049.6A patent/CN120865412A/zh active Pending
- 2019-07-15 SG SG11202012993SA patent/SG11202012993SA/en unknown
- 2019-07-15 KR KR1020217003848A patent/KR20210031932A/ko not_active Ceased
- 2019-07-15 MA MA053122A patent/MA53122A/fr unknown
- 2019-07-15 MY MYPI2020006631A patent/MY205398A/en unknown
- 2019-07-15 CA CA3106146A patent/CA3106146A1/en active Pending
- 2019-07-15 AU AU2019300223A patent/AU2019300223A1/en active Pending
- 2019-07-15 BR BR112020026432-6A patent/BR112020026432A2/pt unknown
- 2019-07-15 TW TW108124908A patent/TW202019518A/zh unknown
-
2020
- 2020-02-10 US US16/786,563 patent/US20200165352A1/en not_active Abandoned
-
2021
- 2021-01-04 IL IL279937A patent/IL279937A/en unknown
- 2021-01-08 PH PH12021550054A patent/PH12021550054A1/en unknown
- 2021-01-08 CL CL2021000066A patent/CL2021000066A1/es unknown
- 2021-01-11 DO DO2021000006A patent/DOP2021000006A/es unknown
- 2021-02-10 CO CONC2021/0001544A patent/CO2021001544A2/es unknown
- 2021-02-11 EC ECSENADI202110092A patent/ECSP21010092A/es unknown
-
2024
- 2024-01-23 US US18/420,021 patent/US20240317881A1/en active Pending
- 2024-03-26 JP JP2024048842A patent/JP2024075737A/ja active Pending
- 2024-10-25 DO DO2024000217A patent/DOP2024000217A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024075737A5 (https=) | ||
| JP2021524276A5 (https=) | ||
| Lou et al. | Antibody variable region engineering for improving cancer immunotherapy | |
| JP2025163055A5 (https=) | ||
| CN103030695B (zh) | 抗c‑Met人源化抗体及含其的预防或治疗癌症用的药物组合物 | |
| JP2021514664A5 (https=) | ||
| JP2022515318A5 (https=) | ||
| JP2022008382A5 (https=) | ||
| JP2021531754A5 (https=) | ||
| EP3885367A1 (en) | Anti-her2/pd1 bispecific antibody | |
| JP2020501531A5 (https=) | ||
| JP2020530298A5 (https=) | ||
| EP3759229A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer | |
| JP2022532991A5 (https=) | ||
| JP2017522871A5 (https=) | ||
| CN104334579A (zh) | 抗c-met抗体及其用途 | |
| CN117946278A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2024521472A5 (https=) | ||
| JP2022526420A5 (https=) | ||
| JP2025508009A5 (https=) | ||
| JP2021528047A5 (https=) | ||
| JP2022526841A5 (https=) | ||
| JP2024016024A5 (https=) | ||
| JP2024508808A5 (https=) | ||
| JP2022527173A5 (https=) |